These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 33642284)
1. TERT Promoter Mutations Correlate with IDHs, MGMT and EGFR in Glioblastoma Multiforme. Tomar MS; Shrivastava A Neurol India; 2021; 69(1):135-136. PubMed ID: 33642284 [No Abstract] [Full Text] [Related]
2. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
3. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
4. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
5. The significance of MGMT methylation in Glioblastoma Multiforme prognosis. Rao AM; Quddusi A; Shamim MS J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme. Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831 [TBL] [Abstract][Full Text] [Related]
7. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
8. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941 [TBL] [Abstract][Full Text] [Related]
9. Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Fietkau R; Putz F; Lahmer G; Semrau S; Buslei R Strahlenther Onkol; 2013 Dec; 189(12):993-5. PubMed ID: 24177536 [No Abstract] [Full Text] [Related]
10. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma. Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
12. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165 [TBL] [Abstract][Full Text] [Related]
13. Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283 [TBL] [Abstract][Full Text] [Related]
14. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
15. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma]. Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643 [No Abstract] [Full Text] [Related]
16. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? Hegi ME; Stupp R Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690 [No Abstract] [Full Text] [Related]
17. [Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results]. Zolotova SV; Anoshkin KI; Absalyamova OV; Makashova ES; Belyashova AS; Telysheva EN; Golanov AV Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(3):33-40. PubMed ID: 35758076 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
19. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756 [TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Simon M; Hosen I; Gousias K; Rachakonda S; Heidenreich B; Gessi M; Schramm J; Hemminki K; Waha A; Kumar R Neuro Oncol; 2015 Jan; 17(1):45-52. PubMed ID: 25140036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]